• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Helicases as antiviral drug targets.作为抗病毒药物靶点的解旋酶
Drug News Perspect. 2003 Jul-Aug;16(6):355-62. doi: 10.1358/dnp.2003.16.6.829307.
2
Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.一种2-氨基噻唑通过与UL5-UL8-UL52复合物的解旋酶成分相互作用抑制单纯疱疹病毒复制
J Virol. 1998 Sep;72(9):6979-87. doi: 10.1128/JVI.72.9.6979-6987.1998.
3
UL52 primase interactions in the herpes simplex virus 1 helicase-primase are affected by antiviral compounds and mutations causing drug resistance.单纯疱疹病毒1型解旋酶-引发酶中UL52引发酶的相互作用受抗病毒化合物和导致耐药性的突变影响。
J Biol Chem. 2014 Nov 21;289(47):32583-92. doi: 10.1074/jbc.M114.609453. Epub 2014 Oct 2.
4
The three-component helicase/primase complex of herpes simplex virus-1.单纯疱疹病毒-1 的三组分解旋酶/引发酶复合物。
Open Biol. 2021 Jun;11(6):210011. doi: 10.1098/rsob.210011. Epub 2021 Jun 9.
5
The UL8 subunit of the herpes simplex virus helicase-primase complex is required for efficient primer utilization.单纯疱疹病毒解旋酶-引发酶复合物的UL8亚基是有效利用引物所必需的。
J Virol. 1992 Aug;66(8):4884-92. doi: 10.1128/JVI.66.8.4884-4892.1992.
6
Understanding helicases as a means of virus control.将解旋酶理解为一种病毒控制手段。
Curr Pharm Des. 2006;12(11):1315-38. doi: 10.2174/138161206776361147.
7
High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.新型抗病毒疗法时代单纯疱疹病毒UL5/UL52解旋酶-引物酶复合物的高度保守性
Antiviral Res. 2016 Apr;128:1-6. doi: 10.1016/j.antiviral.2016.01.015. Epub 2016 Jan 28.
8
Role of the herpes simplex virus helicase-primase complex during adeno-associated virus DNA replication.单纯疱疹病毒解旋酶-引发酶复合物在腺相关病毒DNA复制过程中的作用。
J Virol. 2006 Jun;80(11):5241-50. doi: 10.1128/JVI.02718-05.
9
New anti-HSV therapeutics target the helicase-primase complex.新型抗单纯疱疹病毒疗法以解旋酶-引发酶复合物为靶点。
Nat Med. 2002 Apr;8(4):327-8. doi: 10.1038/nm0402-327.
10
Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.单纯疱疹病毒解旋酶-引发酶抑制剂在人类疾病的动物模型中具有活性。
Nat Med. 2002 Apr;8(4):386-91. doi: 10.1038/nm0402-386.

引用本文的文献

1
Allosteric Regulation of RNA Affinity by Motif V-VI Coupling in West Nile Virus NS3 Helicase.西尼罗河病毒NS3解旋酶中基序V-VI偶联对RNA亲和力的变构调节
bioRxiv. 2025 Jul 4:2025.07.04.663198. doi: 10.1101/2025.07.04.663198.
2
A Comprehensive Survey on the Expediated Anti-COVID-19 Options Enabled by Metal Complexes-Tasks and Trials.金属配合物加速抗 COVID-19 选项的全面调查:任务与试验。
Molecules. 2023 Apr 10;28(8):3354. doi: 10.3390/molecules28083354.
3
Flavivirus proteases: The viral Achilles heel to prevent future pandemics.黄病毒蛋白酶:预防未来大流行的病毒阿喀琉斯之踵。
Antiviral Res. 2023 Feb;210:105516. doi: 10.1016/j.antiviral.2022.105516. Epub 2022 Dec 29.
4
Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro.鞣花酸作为一种别构 NSP13 解旋酶抑制剂,能够在体外有效抑制 SARS-CoV-2 的复制。
Antiviral Res. 2022 Oct;206:105389. doi: 10.1016/j.antiviral.2022.105389. Epub 2022 Aug 17.
5
Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening.通过解旋酶抑制剂再利用靶向 SARS-CoV-2 非结构蛋白 13,并通过基于药效团的筛选靶向非结构蛋白 16。
Mol Divers. 2023 Jun;27(3):1067-1085. doi: 10.1007/s11030-022-10468-8. Epub 2022 Jun 12.
6
Metal-based complexes against SARS-CoV-2.金属基配合物抗 SARS-CoV-2。
Biometals. 2022 Aug;35(4):639-652. doi: 10.1007/s10534-022-00386-5. Epub 2022 Mar 24.
7
Analysing the essential proteins set of Plasmodium falciparum PF3D7 for novel drug targets identification against malaria.分析恶性疟原虫 Pf3D7 的必需蛋白组,寻找针对疟疾的新型药物靶点。
Malar J. 2021 Aug 3;20(1):335. doi: 10.1186/s12936-021-03865-1.
8
The three-component helicase/primase complex of herpes simplex virus-1.单纯疱疹病毒-1 的三组分解旋酶/引发酶复合物。
Open Biol. 2021 Jun;11(6):210011. doi: 10.1098/rsob.210011. Epub 2021 Jun 9.
9
RNA Helicases as Shadow Modulators of Cell Cycle Progression.RNA 解旋酶作为细胞周期进程的影子调控因子。
Int J Mol Sci. 2021 Mar 15;22(6):2984. doi: 10.3390/ijms22062984.
10
Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents.冠状病毒解旋酶:抗病毒药物开发和治疗专利的有吸引力和独特的靶标。
Expert Opin Ther Pat. 2021 Apr;31(4):339-350. doi: 10.1080/13543776.2021.1884224. Epub 2021 Apr 21.

本文引用的文献

1
Hepatitis C virus NS3 ATPases/helicases from different genotypes exhibit variations in enzymatic properties.来自不同基因型的丙型肝炎病毒NS3 ATP酶/解旋酶在酶学特性上存在差异。
J Virol. 2003 Apr;77(7):3950-61. doi: 10.1128/jvi.77.7.3950-3961.2003.
2
Novel agents and strategies to treat herpes simplex virus infections.治疗单纯疱疹病毒感染的新型药物和策略。
Expert Opin Investig Drugs. 2003 Feb;12(2):165-83. doi: 10.1517/13543784.12.2.165.
3
RecQ family helicases: roles as tumor suppressor proteins.RecQ 家族解旋酶:作为肿瘤抑制蛋白的作用。
Oncogene. 2002 Dec 16;21(58):9008-21. doi: 10.1038/sj.onc.1205959.
4
Physical methods to determine the binding mode of putative ligands for hepatitis C virus NS3 helicase.
Anal Biochem. 2002 Oct 15;309(2):186-95. doi: 10.1016/s0003-2697(02)00301-9.
5
Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy.丙型肝炎病毒的核苷酸三磷酸酶/解旋酶作为抗病毒治疗的靶点。
Antiviral Res. 2002 Sep;55(3):397-412. doi: 10.1016/s0166-3542(02)00096-7.
6
Hepatitis C virus NS3 ATPase/helicase: an ATP switch regulates the cooperativity among the different substrate binding sites.丙型肝炎病毒NS3 ATP酶/解旋酶:一种ATP开关调节不同底物结合位点之间的协同作用。
Biochemistry. 2002 Aug 13;41(32):10332-42. doi: 10.1021/bi026082g.
7
Papillomavirus E1 proteins: form, function, and features.乳头瘤病毒E1蛋白:形态、功能及特征
Virus Genes. 2002 Jun;24(3):275-90. doi: 10.1023/a:1015336817836.
8
Helicase from hepatitis C virus, energetics of DNA binding.丙型肝炎病毒解旋酶,DNA结合的能量学
J Biol Chem. 2002 Aug 16;277(33):29377-85. doi: 10.1074/jbc.M112315200. Epub 2002 May 28.
9
Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.单纯疱疹病毒引发酶 - 解旋酶抑制剂BAY 57 - 1293具有强大的体内抗病毒活性。
Antimicrob Agents Chemother. 2002 Jun;46(6):1766-72. doi: 10.1128/AAC.46.6.1766-1772.2002.
10
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease.新型解旋酶-引发酶抑制剂作为治疗单纯疱疹疾病的候选药物。
Nat Med. 2002 Apr;8(4):392-8. doi: 10.1038/nm0402-392.

作为抗病毒药物靶点的解旋酶

Helicases as antiviral drug targets.

作者信息

Frick David N

机构信息

Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY 10595, USA.

出版信息

Drug News Perspect. 2003 Jul-Aug;16(6):355-62. doi: 10.1358/dnp.2003.16.6.829307.

DOI:10.1358/dnp.2003.16.6.829307
PMID:12973446
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3571683/
Abstract

Helicases catalytically unwind duplex DNA or RNA using energy derived from the hydrolysis of nucleoside triphosphates and are attractive drug targets because they are required for viral replication. This review discusses methods for helicase identification, classification and analysis, and presents an overview of helicases that are necessary for the replication of human pathogenic viruses. Newly developed methods to analyze helicases, coupled with recently determined atomic structures, have led to a better understanding of their mechanisms of action. The majority of this research has concentrated on enzymes encoded by the herpes simplex virus (HSV) and the hepatitis C virus (HCV). Helicase inhibitors that target the HSV helicase-primase complex comprised of the UL5, UL8 and UL52 proteins have recently been shown to effectively control HSV infection in animal models. In addition, several groups have reported structures of the HCV NS3 helicase at atomic resolutions, and mechanistic studies have uncovered characteristics that distinguish the HCV helicase from related cellular proteins. These new developments should eventually lead to new antiviral medications.

摘要

解旋酶利用核苷三磷酸水解产生的能量催化解开双链DNA或RNA,由于它们是病毒复制所必需的,因此是有吸引力的药物靶点。本文综述了解旋酶的鉴定、分类和分析方法,并概述了人类致病病毒复制所必需的解旋酶。新开发的解旋酶分析方法,结合最近确定的原子结构,使人们对其作用机制有了更好的理解。这项研究大部分集中在单纯疱疹病毒(HSV)和丙型肝炎病毒(HCV)编码的酶上。最近发现,靶向由UL5、UL8和UL52蛋白组成的HSV解旋酶-引物酶复合物的解旋酶抑制剂能够在动物模型中有效控制HSV感染。此外,几个研究小组报告了HCV NS3解旋酶的原子分辨率结构,机理研究揭示了HCV解旋酶与相关细胞蛋白的区别特征。这些新进展最终应该会带来新的抗病毒药物。